- The ASX200 closed 0.37% lower on Friday at 7342.60 points.
- Computershare hit a 52-week high as founder resigned from the board.
- Paradigm Biopharmaceuticals rallied on approval for phase 3 clinical trial.
The Australian market closed 0.37% lower at 7342.60 on Friday as the gold miners led losses on the ASX with Ramelius Resources posting the greatest loss of 5.73%. The turbulent start to the week meant the ASX posted a 0.83% loss for the week.
The tech sector overturned a morning rally to close lower today as Wisetech Global fell 2.58%, Xero lost 2.52% and Appen closed the session 2.03% lower.
Bitcoin is trading 1.21% higher over the last 24-hours at US$44,363.33 at 4:30pm AEST.
Financial administration company Computershare soared to a 52-week high share price of $17.95 during today?s session following the company announcing that founder, Chris Morris, will leave the board on November 11. Chris Morris will be replaced on the board by John Nendick, a ?senior financial executive who is an expert in new business models, global financial, account and audit matters? and other expertise.
Making headlines, Australian-based Paradigm Biopharma jumped 2.4% today after providing an update on its upcoming clinical trial. Paradigm announced that it has received an Australian ethics approval for its pivotal phase 3 clinical trial in participants with knee osteoarthritis pain. The study will trial Paradigm?s PPS and a placebo given to patients with Osteoarthritis Pain.
And popular digital pet game from 2005, Neopets, is revamping through the launch of its first NFT collection, the Neopets Metaverse collection.